{"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"BG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.62","value":"71.9"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"168"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"295"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Japan"}],"description":"All participants were enrolled in Japan.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.70","value":"157.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"288"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Hight","unitOfMeasure":"Centimeters (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.122","value":"56.91"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"277"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Weight","unitOfMeasure":"Kilograms (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.353","value":"22.96"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"276"}],"units":"Participants"}]}],"description":"Body Mass Index = weight (kg)/\\[height (m)\\^2\\]","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"BMI","unitOfMeasure":"Kilogram (kg)/meter (m)^2]"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.1830","value":"1.562"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"276"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Body Surface Area","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"101"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Missing"}],"description":"International Staging System is a staging system for cancer progression. Stages are classified by Stage I to Stage III. Stage I: Serum beta2-microglobulin \\<3.5 mg/L and albumin ≥3.5 g/dL; Stage II: Neither Stage I or III, meaning that either: beta2-microglobulin level ≥3.5 and \\<5.5 mg/L (with any albumin level), OR albumin \\<3.5 g/dL with beta2-microglobulin \\<3.5 mg/L; Stage III: Serum beta2-microglobulin ≥5.5 mg/L. Normal serum beta2-microglobulin: \\<3.0 mg/L; normal albumin: 3.5-5.0 g/dL.","paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (at Initial Diagnosis)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"130"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Missing"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (at First Treatment)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"90"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"295"}],"units":"Participants"}],"title":"Missing"}],"description":"ECOG P.S. assess participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory ( greater than \\[\\>\\] 50 percent \\[%\\] of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \\>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group performance status (ECOG P.S.)","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib."}